pre-IPO PHARMA

COMPANY OVERVIEW

Carmot Therapeutics is pioneering the discovery and development of innovative drugs for the treatment of metabolic diseases, cancer, and inflammation. Carmot’s vision is to become a leader in drug discovery by generating superior drugs for challenging therapeutic targets. Chemotype Evolution, Carmot’s proprietary technology, enables the rapid identification of novel drugs through an evolutionary discovery paradigm and has produced a pipeline of breakthrough therapeutics currently in pre-clinical development.


LOCATION

  • Berkeley, CA, USA
  • San Francisco, CA, USA

  • THERAPEUTIC AREAS

  • Inflammatory Disease
  • Metabolic Disorders
  • Oncology

  • WEBSITE

    https://carmot-therapeutics.us


    CAREER WEBSITE

    https://carmot-therapeutics.us/careers/


    SOCIAL MEDIA


    INVESTORS

    horizons-ventures jerome-dahan ra-capital the-column-group


    PRESS RELEASES


    Sep 21, 2022

    Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO


    Jul 26, 2022

    Carmot Therapeutics closes $160 million Series D financing to advance clinical pipeline of novel incretin receptor modulators


    Jun 24, 2021

    Carmot Therapeutics Initiates the Clinical Program for CT-388, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Patients with Type 2 Diabetes and Showcases its Technology at the Upcoming American Diabetes Association Scientific Session


    May 4, 2021

    Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients with Type 2 Diabetes


    Mar 17, 2021

    Carmot Therapeutics Expands Leadership Team With Appointment of Manu Chakravarthy, MD, PhD as Chief Medical Officer and Executive Vice President of RandD


    For More Press Releases


    Google Analytics Alternative